Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to

Amarin Announces Notification of Two Additional Patent Allowances for U.S.
Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA
Approved MARINE Indication

Strengthens Positioning of Vascepa for Exclusivity Into 2030

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that the United States Patent and Trademark Office
(USPTO) has published notification of Notices of Allowance for Amarin's U.S.
Patent Applications Serial Numbers 13/458,496 and 13/349,157.

The allowed '496 and '157 applications continue to broaden our claimed methods
of reducing triglycerides consistent with the FDA approved MARINE indication
for Vascepa® capsules through use of a pharmaceutical composition of highly
pure icosapent ethyl, or EPA.

A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patents would have terms
that expire no earlier than in 2030. After issuance, Amarin plans to list
these patents in the FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations, or Orange Book.

"The issuance of these Notices of Allowance further strengthens Amarin's
effort to protect the commercial potential of Vascepa," said Joseph
Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin now has 15
patents either issued or allowed that position Vascepa for exclusivity to 2030
and beyond."

Amarin now has 15 U.S. patents either issued or allowed and over 30 additional
patent applications currently in prosecution in the United States. Amarin is
also pursuing patent applications related to Vascepa in multiple jurisdictions
outside the United States, including the application for Amarin's MARINE
method of use patent in Europe for which Amarin has announced receipt of an
Intention to Grant letter.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patents would be issued and adequately protect
Vascepa against competition, the expiration date of the pending patents,
Amarin's plan to list the patents, when issued, in the FDA's Orange Book,
Amarin's plan to protect the commercial potential of Vascepa, and the future
status of pending patent applications. These forward-looking statements are
not promises or guarantees and involve substantial risks and uncertainties.
Among the factors that could cause actual results to differ materially from
those described or projected herein include the following: events that could
interfere with the issuance of a patent, or once issued, the continued
validity or enforceability of a patent; Amarin's ability generally to maintain
adequate patent protection and successfully enforce patent claims against
third parties; commercializing Vascepa without violating the intellectual
property rights of others; and uncertainties associated generally with
research and development, clinical trials and related regulatory approvals. A
further list and description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Amarin undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise.

CONTACT: Stephen D. Schultz
         Senior Director, Investor Relations
         and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.